To further increase its sensitivity to osimertinib‐resistant lung cancer cells, the liposomal PROTAC is encapsulated with class I HDAC inhibitor MS‐275 (GM‐protac) by both blocking the EGFR‐dependent pathways and bypass resistant mechanisms. The gene discussed is EGFR; the disease is lung carcinoma.